Therefore, GD2-CARrejTs that express both TIGIT and PD-1 at low levels can sustain cytotoxic activity with diminished susceptibility to exhaustion, a feature that holds therapeutic promise against SCLC. The gene discussed is PDCD1; the disease is small cell lung carcinoma.